Novo Nordisk sinks 10% after weight loss drug fails to match Eli Lilly's in trial - CNBC
AI Summary1 min read
TL;DR
Novo Nordisk's stock dropped 10% after its next-generation weight loss drug failed to outperform Eli Lilly's rival in a clinical trial, leading to negative market reactions.
Tags
Novo Nordiskweight loss drugEli Lillyclinical trialstock decline
- Novo Nordisk sinks 10% after weight loss drug fails to match Eli Lilly's in trial CNBC
- Novo Nordisk's obesity drug falls short against Eli Lilly's in trial Reuters
- Novo’s Next-Generation Obesity Shot Falls Short of Lilly Rival Bloomberg
- Novo Nordisk Shares Slide After Obesity Drug Misses Key Goal in Trial The Wall Street Journal
- Novo Nordisk’s next-gen obesity drug stumbles in comparison study statnews.com